Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)

Trial Profile

Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tinzaparin sodium (Primary)
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms PREDICARE
  • Sponsors LEO Pharma
  • Most Recent Events

    • 12 Dec 2023 Results (n=1413) a meta-analysis from this and NCT02898051, NCT01164046 and NCT01130025 studies on individual patient level data to report the rate of rVTE and MB by 6 months according to site of cancer from prospective studies involving CAT patients on tinzaparin, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 20 Apr 2021 Results published in the Thrombosis and Haemostasis
    • 31 May 2020 Primary endpoint has not been met. (Venous thromboembolism recurrence), as reported in an abstract presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top